New cell therapy aims to stop deadly childhood leukemia from coming back
NCT ID NCT07476027
First seen Mar 24, 2026 · Last updated May 16, 2026 · Updated 11 times
Summary
This early-phase trial tests a new treatment called CD7 CAR-T cell therapy in 10 children with high-risk T-cell leukemia or lymphoma. After standard chemotherapy puts the cancer into remission, the child's own immune cells are collected, modified to better attack cancer cells, and given back. The goal is to see if this approach is safe and can keep the cancer from returning.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for T ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.